Study Summary
This trial will compare the effectiveness of different RA treatments in patients who have not responded to a TNFi biologic.
- Rheumatoid Arthritis
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Change from baseline to 12 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
4 Treatment Groups
non-TNFi-biologic class
1 of 4
tsDMARD class
1 of 4
TNFi-biologic class
1 of 4
targeted synthetic DMARD class
1 of 4
Active Control
924 Total Participants · 4 Treatment Groups
Primary Treatment: non-TNFi-biologic class · No Placebo Group · Phase 3
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Who else is applying?
What state do they live in?
Alabama | 100.0% |
How old are they?
18 - 65 | 100.0% |
What site did they apply to?
University of Alabama at Birmingham | 100.0% |
What portion of applicants met pre-screening criteria?
Met criteria | 100.0% |
Frequently Asked Questions
How many test subjects are you taking on for this experiment?
"That is correct, the online information does state that the researchers are currently looking for individuals to take part in this trial. This specific study was posted on September 22nd 2021 and updated June 9th 2022. They are expecting a total of 924 participants from 1 location." - Anonymous Online Contributor
What are the risks associated with non-TNFi-biologic class medication?
"There is some evidence to support the efficacy of non-TNFi-biologic class drugs, as well as data from multiple rounds of testing that suggest these medications are safe. Consequently, our team has given them a score of 3." - Anonymous Online Contributor